Trial intelligence / Profile preview

Dexmedetomidine preconditioning in pediatric living-donor liver transplantation

ChiCTR2000040680Phase 4Recruiting

Sponsor
Beijing Friendship Hospital
Start
Dec 2020
Modality
Small Molecules
Countries
1
01

Overview

Phase 4, randomised trial of dexmedetomidine in hepatic ischemia-reperfusion injury (HIRI) (2 arms), sponsored by Beijing Friendship Hospital. Primary endpoints: Postoperative liver transaminase levels and Severity of hepatic ischemia-reperfusion injury. Started Dec 2020; status: recruiting.

02

Drugs

dexmedetomidine
03

Conditions

hepatic ischemia-reperfusion injury (HIRI)

Beyond the preview

Go deeper on ChiCTR2000040680.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2000040680.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call